Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022

Dec 10

Written By Kayla (Gyebang) Mo

Poster Title: ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML

Date and Time: 12/10/2022, 5:30 PM to 7:30 PM CST

Kayla (Gyebang) Mo

Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022

Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1